Non-Coding mRNA: Merck & Co' Novel Drug Target For Antibacterials And Possibly Human Disease
This article was originally published in Scrip
Merck & Co researchers have found a small-molecule modulator of non-coding elements in bacterial mRNA that points the way to the development of new antibacterials with a totally new mode of action, and possibly novel medicines for human disease too.
You may also be interested in...
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis and Pfizer are helping to fund a public-private partnership aimed at improving the primary care health infrastructure in Africa; the collaboration will also exploit the companies’ experience providing therapies and using digital and web-enabled technologies.
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.